Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques
- PMID: 16185742
- DOI: 10.1016/j.virol.2005.08.027
Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques
Abstract
Here, we study immune responses in four DNA/MVA-vaccinated macaques following an SHIV-89.6P challenge and a subsequent CD8 cell depletion. Both post-challenge and post-depletion peaks of viremia contracted with the expansion, or re-emergence, of CD8 T cells. Post-depletion, CD8 cells expanded in the presence of higher levels of neutralizing Ab and CD4 help than post-challenge and had superior maturational characteristics as measured by expression of the anti-apoptotic protein Bcl-2, the IL-7 receptor CD127 and co-production of IFN-gamma and IL-2. Pre-challenge and pre-depletion titers of neutralizing Ab correlated inversely with peaks of viremia and directly with peaks for anti-viral CD4 cells. Thus, our results reveal CD8 cells playing a central role, and neutralizing Ab, a supporting role in SHIV-89.6P control. They also suggest a dynamic relationship between neutralizing Ab, antigen load and anti-viral CD4 cells in the maturation of high-quality anti-viral CD8 T cells.
Similar articles
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005. J Virol. 2005. PMID: 16160159 Free PMC article.
-
Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.Vaccine. 2007 Jun 21;25(26):4967-82. doi: 10.1016/j.vaccine.2006.11.070. Epub 2007 Feb 14. Vaccine. 2007. PMID: 17335943
-
Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.Vaccine. 2008 Dec 2;26(51):6690-8. doi: 10.1016/j.vaccine.2008.07.055. Vaccine. 2008. PMID: 18694796
-
CD8(+) T cells in preventing HIV infection and disease.AIDS. 2012 Jun 19;26(10):1281-92. doi: 10.1097/QAD.0b013e328353bcaf. AIDS. 2012. PMID: 22441256 Review.
-
CTL ontogeny and viral escape: implications for HIV-1 vaccine design.Trends Immunol. 2004 Mar;25(3):138-42. doi: 10.1016/j.it.2004.01.004. Trends Immunol. 2004. PMID: 15036041 Review. No abstract available.
Cited by
-
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.PLoS One. 2010 Aug 24;5(8):e12395. doi: 10.1371/journal.pone.0012395. PLoS One. 2010. PMID: 20811493 Free PMC article.
-
An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design.Vaccines (Basel). 2019 Dec 6;7(4):208. doi: 10.3390/vaccines7040208. Vaccines (Basel). 2019. PMID: 31817622 Free PMC article.
-
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.J Virol. 2009 Jun;83(11):5881-9. doi: 10.1128/JVI.02345-08. Epub 2009 Mar 25. J Virol. 2009. PMID: 19321612 Free PMC article. Clinical Trial.
-
Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B.Vaccines (Basel). 2020 Feb 6;8(1):70. doi: 10.3390/vaccines8010070. Vaccines (Basel). 2020. PMID: 32041218 Free PMC article.
-
DNA vaccines for HIV: challenges and opportunities.Springer Semin Immunopathol. 2006 Nov;28(3):267-79. doi: 10.1007/s00281-006-0046-z. Epub 2006 Oct 10. Springer Semin Immunopathol. 2006. PMID: 17031649 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials